Cabazitaxel (Jevtana®)

Common name: Cabazitaxel
Brand name: Jevtana®

What is Cabazitaxel?

Cabazitaxel is a chemotherapy drug used to treat advanced (metastatic) prostate cancer when hormonal therapy is no longer able to control the cancer. Cabazitaxel, used in combination with a corticosteroid (such as prednisone or prednisolone), is often given to men after they have been treated with docetaxel, another chemotherapy drug.

How is Cabazitaxel administered?

Cabazitaxel is administered by injection.

What are possible side effects of this treatment?

Everyone responds differently to chemotherapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received cabazitaxel. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Abdominal pain
  • Anemia (low red blood cell count)
  • Bruising / bleeding    
  • Blood in urine (hematuria)
  • Constipation    
  • Diarrhea            
  • Fatigue
  • Infection
  • Kidney problems
  • Loss of appetite
  • Muscle weakness
  • Neutropenia (low white blood cell count)
  • Numbness / tingling in hands and feet

Is Cabazitaxel covered in my province or territory?*    

Cabazitaxel is covered by provincial drug programs in:
  • Alberta
  • British Columbia (restricted)
  • Ontario
  • Newfoundland & Labrador
  • Nova Scotia
  • Saskatchewan
Cabazitaxel is not covered by provincial drug programs in:
  • New Brunswick
  • Prince Edward Island
  • Quebec
  • Nunavut
  • Northwest Territories
  • Yukon
Cabazitaxel may be covered by provincial drug programs after individual review in:
  • ​Manitoba​
Last Reviewed: July 2017



Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.

12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.

Click here for news archive